STOCK TITAN

Biocryst Pharmaceuticals Inc. - BCRX STOCK NEWS

Welcome to our dedicated news page for Biocryst Pharmaceuticals (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biocryst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biocryst Pharmaceuticals's position in the market.

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has received approval from the Brazilian Health Regulatory Agency for ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients. This approval marks a significant milestone for BioCryst as they expand their market presence in Latin America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. granted six newly-hired employees stock options and restricted stock units as inducements for joining the company. The options and RSUs total 43,975 and 30,625 shares respectively, with an exercise price of $5.08 per share. Vesting occurs in four equal annual installments starting on the one-year anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) will present at two upcoming virtual healthcare conferences, showcasing their latest developments. The presentations can be accessed via live audio webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
conferences
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. granted three newly-hired employees stock options and RSUs as inducements for entering employment. The options and RSUs total 16,050 and 11,300 shares respectively, with an exercise price of $5.63 per share. They vest in four equal annual installments, subject to continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. reported strong financial results for Q4 2023 and FY 2023, with ORLADEYO net revenue reaching $90.9 million for Q4 and $326.0 million for FY 2023, showing a 30% year-over-year increase. The company expects ORLADEYO net revenue to reach $380-$400 million in 2024, with operating profit anticipated in 2024 and positive cash flow in 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) announced new analyses showing rapid, substantial, and sustained reductions in hereditary angioedema (HAE) attack rates with ORLADEYO. The data presented at the AAAAI annual meeting demonstrate the effectiveness of ORLADEYO in controlling HAE attacks regardless of disease severity, prior prophylaxis, or C1-INH level. Real-world outcomes highlight significant benefits for patients initiating ORLADEYO, with consistent attack rate reductions observed over 18 months of treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) will present at two upcoming healthcare conferences in March 2024, providing investors with valuable insights. The presentations will be held at the TD Cowen 44th Annual Health Care Conference and the Barclays 26th Annual Global Healthcare Conference, offering live audio webcasts and replays for interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
conferences
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) receives a positive recommendation from the Italian Medicines Agency for ORLADEYO® (berotralstat) for the prevention of recurrent attacks of hereditary angioedema (HAE) in Italy, expanding access to a groundbreaking therapy for eligible patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) will report its fourth quarter 2023 financial results on February 26, 2024. The company will host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences earnings
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is set to present five abstracts at the 2024 American Academy of Allergy, Asthma & Immunology annual meeting, focusing on the real-world use of ORLADEYO for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older. The abstracts feature new analyses and will cover topics such as reduction of HAE attack rates, tolerability, adherence, and effectiveness of berotralstat in patients with HAE, with and without C1-inhibitor deficiency. The meeting will take place from February 23-26, 2024, at the Walter E. Washington Convention Center in Washington, D.C.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
Biocryst Pharmaceuticals Inc.

Nasdaq:BCRX

BCRX Rankings

BCRX Stock Data

950.35M
190.88M
1.21%
88.11%
15.65%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Durham

About BCRX

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.